New drugs: Evolocumab

Australian Prescriber

Volumn 39, Issue 5, 2016, Pages 180-182

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9; TRIACYLGLYCEROL;

BACKACHE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLUENZA; INJECTION SITE ERYTHEMA; MYALGIA; NOTE; UPPER RESPIRATORY TRACT INFECTION;

EID: 85019682953     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2016.078     Document Type: Note

References (10)

1. Page MM, Watts GF. PCSK9 inhibitors mechanisms of action. Aust Prescr 2016;39:164-7. http://dx.doi.org/10.18773/austprescr.2016.060
2. Schmidli R. PCSK9 inhibitors clinical applications. Aust Prescr 2016;39:168-70. http://dx.doi.org/10.18773/austprescr.2016.061
3. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al.; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebocontrolled trial. Lancet 2015;385:341-50. http://dx.doi.org/10.1016/S0140-6736(14)61374-X
4. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, et al.; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:331-40. http://dx.doi.org/10.1016/S0140-6736(14)61399-4
5. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al.; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311:1870-82. http://dx.doi.org/10.1001/jama.2014.4030
6. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al.; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19. http://dx.doi.org/10.1056/NEJMoa1316222
7. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al.; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2531-40. http://dx.doi.org/10.1016/j.jacc.2014.03.018
8. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al.; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2541-8. http://dx.doi.org/10.1016/j.jacc.2014.03.019
9. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and metaanalysis. Ann Intern Med 2015;163:40-51. http://dx.doi.org/10.7326/M14-2957
10. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. http://dx.doi.org/10.1056/NEJMoa1500858